A191420 Stock Overview
A biotechnology-based cosmetics company, engages in the production and sale of skin cell therapy products from human epithelial cells in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
TegoScience Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩15,060.00 |
| 52 Week High | ₩26,100.00 |
| 52 Week Low | ₩10,500.00 |
| Beta | 0 |
| 11 Month Change | -1.70% |
| 3 Month Change | -19.89% |
| 1 Year Change | 37.91% |
| 33 Year Change | -29.13% |
| 5 Year Change | -35.50% |
| Change since IPO | -3.00% |
Recent News & Updates
Shareholder Returns
| A191420 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -0.3% | -3.0% | 2.3% |
| 1Y | 37.9% | 22.4% | -3.8% |
Return vs Industry: A191420 exceeded the KR Biotechs industry which returned 22.4% over the past year.
Return vs Market: A191420 exceeded the KR Market which returned -3.8% over the past year.
Price Volatility
| A191420 volatility | |
|---|---|
| A191420 Average Weekly Movement | 6.2% |
| Biotechs Industry Average Movement | 8.1% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in KR Market | 11.4% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A191420 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A191420's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 51 | Saewha Jeon | www.tegoscience.com |
TegoScience Inc., a biotechnology-based cosmetics company, engages in the production and sale of skin cell therapy products from human epithelial cells in South Korea. The company’s products include Holoderm, Kaloderm, and Rosmir. It also provides Neoderm, contract research, and Skinbank services.
TegoScience Inc. Fundamentals Summary
| A191420 fundamental statistics | |
|---|---|
| Market cap | ₩120.42b |
| Earnings (TTM) | ₩3.65b |
| Revenue (TTM) | ₩6.93b |
33.0x
P/E Ratio17.4x
P/S RatioIs A191420 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A191420 income statement (TTM) | |
|---|---|
| Revenue | ₩6.93b |
| Cost of Revenue | ₩2.23b |
| Gross Profit | ₩4.70b |
| Other Expenses | ₩1.04b |
| Earnings | ₩3.65b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 456.08 |
| Gross Margin | 67.79% |
| Net Profit Margin | 52.72% |
| Debt/Equity Ratio | 2.6% |
How did A191420 perform over the long term?
See historical performance and comparison